Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment.

[1]  L. Dennerstein.  Clinical and Research Perspective , 2001, Journal of sex & marital therapy.

[2]  Dan J Stein.  Social Phobia: Clinical and Research Perspectives , 1999, CNS Spectrums.

[3]  D. Klein,et al.  Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. , 1998, Archives of general psychiatry.

[4]  R. Lydiard,et al.  The role of drug therapy in social phobia. , 1998, Journal of affective disorders.

[5]  M. Stein,et al.  Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. , 1998, JAMA.

[6]  R. Kessler,et al.  Social phobia subtypes in the National Comorbidity Survey. , 1998, The American journal of psychiatry.

[7]  D. Stein,et al.  Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia. , 1998, Journal of affective disorders.

[8]  H. Wittchen,et al.  Prevalence of mental disorders and psychosocial impairments in adolescents and young adults , 1998, Psychological Medicine.

[9]  M. Liebowitz,et al.  Placebo-controlled trial of moclobemide in social phobia , 1998, British Journal of Psychiatry.

[10]  Y. Lecrubier,et al.  Comorbidities in social phobia , 1997, International clinical psychopharmacology.

[11]  S. Montgomery,et al.  Social phobia: long‐term treatment outcome and prediction of response - a moclobemide study , 1997, International clinical psychopharmacology.

[12]  J. Davidson,et al.  Moclobemide in social phobia: a controlled dose-response trial. , 1997, Journal of clinical psychopharmacology.

[13]  K. Kobak,et al.  Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. , 1997, Journal of clinical psychopharmacology.

[14]  H. Westenberg,et al.  Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls , 1997, Biological Psychiatry.

[15]  S. Khanna,et al.  An investigation into the psychobiology of social phobia: personality domains and serotonergic function , 1997, Acta psychiatrica Scandinavica.

[16]  D. Caldirola,et al.  The 35% CO2 challenge test in patients with social phobia , 1997, Psychiatry Research.

[17]  H. Westenberg,et al.  Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. , 1997, The Journal of clinical psychiatry.

[18]  L. H. Taylor,et al.  Fluoxetine efficacy in social phobia. , 1997, The Journal of clinical psychiatry.

[19]  T. Uhde,et al.  A Comparison of the Effects of Intravenous Pentagastrin on Patients with Social Phobia, Panic Disorder and Healthy Controls , 1997, Neuropsychopharmacology.

[20]  J. Tiihonen,et al.  Dopamine reuptake site densities in patients with social phobia. , 1997, The American journal of psychiatry.

[21]  R. Kessler,et al.  Reliability and procedural validity of UM-CIDI DSM-III-R phobic disorders , 1996, Psychological Medicine.

[22]  H. Westenberg,et al.  Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response. , 1996, Journal of affective disorders.

[23]  D. Nutt,et al.  Moclobemide in the treatment of social phobia , 1996, International clinical psychopharmacology.

[24]  H. Kraemer,et al.  Comorbidity and Boundaries of Affective Disorders with Anxiety Disorders and Substance Misuse: Results of an International Task Force , 1996, British Journal of Psychiatry.

[25]  M. Versiani,et al.  The long-term treatment of social phobia with moclobemide , 1996, International clinical psychopharmacology.

[26]  H. Wittchen,et al.  The impact of social phobia on quality of life , 1996, International clinical psychopharmacology.

[27]  M. Stein,et al.  Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. , 1996, Journal of clinical psychopharmacology.

[28]  J. Lépine,et al.  Comorbidity and social phobia: clinical and epidemiological issues , 1996, International clinical psychopharmacology.

[29]  J. Pine,et al.  Comorbidity and social phobia: clinical and epidemiological issues , 1996 .

[30]  J. Lépine,et al.  Social phobia in primary care: level of recognition and drug use , 1996, International clinical psychopharmacology.

[31]  A. Nardi,et al.  The long-term treatment of social phobia with moclobemide. , 1996 .

[32]  J. Mendel.  Social phobia: Clinical and research perspectives , 1996 .

[33]  R. Kessler,et al.  Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. , 1996, Archives of general psychiatry.

[34]  P. Boyer,et al.  Social Phobia in General Health Care: An Unrecognised Undertreated Disabling Disorder , 1996, British Journal of Psychiatry.

[35]  D. Bailly.  The Role of β-Adrenoceptor Blockers in the Treatment of Psychiatric Disorders , 1996 .

[36]  M. Stein,et al.  Plasma neuropeptide Y in anxiety disorders: findings in panic disorder and social phobia , 1996, Psychiatry Research.

[37]  S. Hirsch,et al.  A One Year Prospective Study of the Effect of Life Events and Medication in the Aetiology of Schizophrenic Relapse , 1996, British Journal of Psychiatry.

[38]  M. Humble,et al.  Social phobia: the clinical efficacy and tolerability of the monoamine oxidase ‐A and serotonin uptake inhibitor brofaromine. A double‐blind placebo‐controlled study , 1995, Acta psychiatrica Scandinavica.

[39]  R. Lydiard,et al.  Treatment Options for Social Phobia , 1995 .

[40]  F. Schneier.  Clinical Assessment Strategies for Social Phobia , 1995 .

[41]  K. Kobak,et al.  Sertraline for social phobia: a double-blind, placebo-controlled crossover study. , 1995, The American journal of psychiatry.

[42]  M. Stein,et al.  [3H Paroxetine binding to platelets of patients with social phobia: Comparison to patients with panic disorder and healthy volunteers , 1995, Biological Psychiatry.

[43]  J. Davidson,et al.  The boundary of social phobia. Exploring the threshold. , 1994, Archives of general psychiatry.

[44]  E. Leinonen,et al.  Citalopram in the treatment of social phobia: a report of three cases. , 1994, Pharmacopsychiatry.

[45]  L. Robins.  THE COMPOSITE INTERNATIONAL DIAGNOSTIC INTERVIEW (CIDI) , 1994 .

[46]  J. Lépine,et al.  Social phobia in general health care , 1994, European Neuropsychopharmacology.

[47]  M. Liebowitz,et al.  Functional impairment in social phobia. , 1994, The Journal of clinical psychiatry.

[48]  P. Murali Doraiswamy,et al.  Magnetic resonance imaging in social phobia , 1994, Psychiatry Research.

[49]  M. Stein,et al.  Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxiety. , 1994, The American journal of psychiatry.

[50]  R. Mailman,et al.  Neuroendocrine responsivity to monoaminergic system probes in generalized social phobia. , 1994, Anxiety.

[51]  J. Ross.  Social phobia: the consumer's perspective. , 1993, The Journal of clinical psychiatry.

[52]  J. Davidson,et al.  Treatment of social phobia with clonazepam and placebo. , 1993, Journal of clinical psychopharmacology.

[53]  E. Hollander,et al.  Buspirone in social phobia. , 1993, Journal of clinical psychopharmacology.

[54]  J. Davidson,et al.  The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study , 1993, Psychological Medicine.

[55]  J. Rapoport,et al.  Obsessive compulsive disorder in children and adolescents: issues in management. , 1993, The Journal of clinical psychiatry.

[56]  M. Liebowitz,et al.  Pharmacotherapy of Social Phobia , 1992, British Journal of Psychiatry.

[57]  M. Weissman,et al.  Social Phobia: Comorbidity and Morbidity in an Epidemiologic Sample , 1992 .

[58]  J Gorman,et al.  Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. , 1992, Archives of general psychiatry.

[59]  M. Stein,et al.  Heart rate and plasma norepinephrine responsivity to orthostatic challenge in anxiety disorders. Comparison of patients with panic disorder and social phobia and normal control subjects. , 1992, Archives of general psychiatry.

[60]  J. Kagan,et al.  Comorbidity of parental anxiety disorders as risk for childhood-onset anxiety in inhibited children. , 1992 .

[61]  H. Westenberg,et al.  Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor , 1992, European Neuropsychopharmacology.

[62]  E. Hollander,et al.  Fluoxetine in social phobia. , 1992, Journal of clinical psychopharmacology.

[63]  K. Krishnan,et al.  Levels of urinary free cortisol in social phobia. , 1991, The Journal of clinical psychiatry.

[64]  M. Tancer,et al.  Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. , 1991, Archives of general psychiatry.

[65]  W. Agras,et al.  The assessment and treatment of performance anxiety in musicians. , 1991, The American journal of psychiatry.

[66]  J. Rosenbaum,et al.  Clonazepam for the treatment of social phobia. , 1990, The Journal of clinical psychiatry.

[67]  David H. Barlow,et al.  Syndrome comorbidity in patients diagnosed with a DSM-III-R anxiety disorder. , 1990, Journal of abnormal psychology.

[68]  M. Stein,et al.  The hypothalamic-pituitary-thyroid axis in social phobia. , 1990, The American journal of psychiatry.

[69]  D. Regier,et al.  Age at onset of selected mental disorders in five community populations. , 1990, Archives of general psychiatry.

[70]  A. Ontiveros,et al.  Social Phobia and Clonazepam , 1990, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[71]  D. Munjack,et al.  Clonazepam in the treatment of social phobia: a pilot study. , 1990, The Journal of clinical psychiatry.

[72]  P. Joyce,et al.  Christchurch Psychiatric Epidemiology Study, Part I: Methodology and Lifetime Prevalence for Specific Psychiatric Disorders , 1989, The Australian and New Zealand journal of psychiatry.

[73]  R. Noyes,et al.  Alprazolam treatment of avoidant personality traits in social phobic patients. , 1989, The Journal of clinical psychiatry.

[74]  A. Caspi,et al.  Moving away from the World: Life-Course Patterns of Shy Children. , 1988 .

[75]  Craig A. Anderson,et al.  Brief Report: Discriminating Between Problems in Living: An Examination of Measures of Depression, Loneliness, Shyness, and Social Anxiety , 1988 .

[76]  R. Noyes,et al.  Anxiety symptoms distinguishing social phobia from panic and generalized anxiety disorders. , 1988, The Journal of nervous and mental disease.

[77]  M. Liebowitz,et al.  Tranylcypromine in social phobia. , 1988, Journal of clinical psychopharmacology.

[78]  J. Gorman,et al.  Epinephrine infusions in patients with social phobia. , 1988, The American journal of psychiatry.

[79]  S. Phillips,et al.  Shyness and Dysfunction in Career Development. , 1988 .

[80]  R. Bland,et al.  LIFETIME PREVALENCE OF PSYCHIATRIC DISORDERS IN EDMONTON , 1988, Acta psychiatrica Scandinavica. Supplementum.

[81]  L. Solyom,et al.  Delineating Social Phobia , 1986, British Journal of Psychiatry.

[82]  K. Larkin,et al.  Situational determinants of social anxiety in clinic and nonclinic samples: physiological and cognitive correlates. , 1986, Journal of consulting and clinical psychology.

[83]  J. Gorman,et al.  Specificity of lactate infusions in social phobia versus panic disorders. , 1985, The American journal of psychiatry.

[84]  J. Gorman,et al.  Social phobia. Review of a neglected anxiety disorder. , 1985, Archives of general psychiatry.

[85]  M. Gelder,et al.  Social Phobia: A Comparative Clinical Study , 1983, British Journal of Psychiatry.

[86]  L. Robins,et al.  National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity. , 1981, Archives of general psychiatry.

[87]  J. Mullaney,et al.  Alcohol Dependence and Phobias: Clinical Description and Relevance , 1979, British Journal of Psychiatry.

[88]  D. Rosielle,et al.  Psychiatry , 1905, NeuroImage.

[89]  J. Kelsey,et al.  Venlafaxine in social phobia. , 1995, Psychopharmacology bulletin.

[90]  M. Stein,et al.  Serum interleukin-2 and soluble interleukin-2 receptor levels in generalized social phobia. , 1994, Anxiety.

[91]  R. Kessler,et al.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. , 1994, Archives of general psychiatry.

[92]  E. Hollander,et al.  Diagnostic and substance specificity of carbon-dioxide-induced panic. , 1993, The American journal of psychiatry.

[93]  Social phobia: an overview of treatment strategies. , 1993, The Journal of clinical psychiatry.

[94]  D. Regier,et al.  The epidemiology of anxiety disorders: the Epidemiologic Catchment Area (ECA) experience. , 1990, Journal of psychiatric research.

[95]  J. Kagan,et al.  Psychiatric correlates of behavioral inhibition in young children of parents with and without psychiatric disorders. , 1990, Archives of general psychiatry.

[96]  P. Clayton,et al.  The comorbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression. , 1990, The Journal of clinical psychiatry.

[97]  B. Burns,et al.  Gender differences in phobias: Results of the ECA community survey , 1988 .

[98]  J. Ballenger,et al.  Alprazolam in the treatment of social phobia. , 1988, The Journal of clinical psychiatry.

[99]  J. Gorman,et al.  Psychopharmacological treatment of social phobia. , 1985, Psychopharmacology bulletin.

[100]  C. Dancu,et al.  Physiological, cognitive and behavioral aspects of social anxiety. , 1985, Behaviour research and therapy.

[101]  Burns Le.  The epidemiology of fears and phobias in general practice. , 1980 .

[102]  L E Burns,et al.  The epidemiology of fears and phobias in general practice. , 1980, The Journal of international medical research.